Archives
-
Smoothened Signaling and Olfaction in Honeybees
2026-08-31
Guo et al. characterize Smoothened (Smo) in Apis mellifera and connect Hedgehog pathway perturbation with antennal receptor expression, electroantennographic responses, and odor-guided behavior. The study extends Smo research into insect sensory biology while showing why agonist dose, exposure route, and model context must be validated independently.
-
Tanshinone IIA Rewires Psoriasis Inflammation
2026-08-31
This study combines network pharmacology, molecular docking, keratinocyte experiments, and an imiquimod-induced mouse model to examine how tanshinone IIA from Xiao-Yin decoction affects psoriasis-like inflammation. Its central finding is that tanshinone IIA suppresses IL-17/IL-23 and PTGS2/NF-κB/AP-1 signaling, with stronger pathway inhibition reported when combined with methotrexate.
-
Spatial Sampling of Disease in Beetle Colonies
2026-08-30
Masoudi, Joseph, and Keyhani present an integrated protocol for studying infection dynamics and pathogen movement in social ambrosia beetle colonies. The workflow combines Xyleborus affinis rearing, Metarhizium infection assays, transmission experiments, spatial CFU analysis, fluorescence imaging, and cryo-sectioning to connect colony organization with microbial spread.
-
Cell Cycle Assay Kit: From DNA Content to Mechanism
2026-08-29
Discover how the Cell Cycle Assay Kit (K2263) converts DNA-content measurements into mechanistic insight for drug-response studies. This guide connects PI/RNase A flow cytometry with panobinostat research in MLL-rearranged leukemia while emphasizing controls, interpretation, and assay limitations.
-
Thiazolyl Acetamides as Src Kinase Inhibitors
2026-08-28
The 2011 European Journal of Medicinal Chemistry study used scaffold modification of KX2-391 to examine how replacing its pyridine ring with thiazole and varying the N-benzyl group affected Src inhibition and cancer-cell proliferation. The work identified measurable structure–activity relationships, while also showing why substrate-site kinase inhibition requires careful separation of biochemical selectivity from cellular antiproliferative effects.
-
EZ Cap™ Cre mRNA: A Functional Delivery Benchmark
2026-08-28
EZ Cap™ Cre mRNA (m1Ψ) can do more than drive transient recombination: it can help researchers dissect mRNA delivery, translation, and functional protein activity. This article connects the reagent’s molecular design with practical assay decisions inspired by emerging extrahepatic delivery platforms.
-
Cisplatin (CDDP): Mechanism and Research Workflow
2026-08-27
Cisplatin (CDDP) is a platinum-based DNA crosslinking agent that produces guanine adducts, replication stress, and apoptosis in susceptible cancer cells. This guide connects its molecular mechanism with apoptosis assays, xenograft research, resistance studies, and evidence-based handling of SKU A8321.
-
Nilotinib (AMN-107): Reliable Assay Workflows
2026-08-27
This scenario-driven guide shows how Nilotinib (AMN-107), SKU A8232, can support interpretable cell viability, proliferation, cytotoxicity, and kinase-signaling experiments. It connects formulation data with practical controls, mechanistic readouts, and vendor-selection criteria for chronic myeloid leukemia research and related kinase models.
-
S. eriocheiris Entry into Drosophila S2 Cells
2026-08-26
Wei and colleagues established a Drosophila Schneider 2 cell model to show that Spiroplasma eriocheiris invades invertebrate cells through clathrin-mediated endocytosis and macropinocytosis. Pharmacological perturbation and cytoskeletal studies connect bacterial internalization with clathrin, macropinocytic signaling, actin, and microtubule function, while also revealing infection-associated oxidative stress and cell damage.
-
DAT PET Tracks Dopaminergic Neuron Maturation
2026-08-26
Goggi et al. showed that longitudinal dopamine transporter PET can assess the survival, maturation, and presynaptic integration of transplanted human embryonic stem cell-derived midbrain dopaminergic neurons in a rat model of Parkinson’s disease. The study demonstrates why imaging should be interpreted alongside behavioral and histological endpoints when evaluating cell-replacement therapies.
-
PPM-18: Reading iNOS Signals in Redox Assays
2026-08-25
PPM-18 is an iNOS expression inhibitor that helps separate NF-κB-driven inflammatory transcription from broader redox signaling. This article uses cardiac redox biology to develop a more rigorous framework for assay design, controls, and interpretation in inflammation and sepsis research.
-
Cuproptosis Signatures for Glioma Treatment
2026-08-25
The reference study developed a cuproptosis-related gene signature to classify gliomas by copper-homeostatic state, clinical risk, and potential sensitivity to elesclomol. Its integrated transcriptomic, clinical, and experimental strategy links worsening glioma grade with copper dysregulation and provides a framework for testing copper-dependent treatment hypotheses.
-
S Tag Peptide: Fusion Tag Workflow Guide
2026-08-24
S Tag Peptide is a short, highly soluble RNase A-derived tag used to support recombinant protein detection, antibody-based capture, and protein solubility improvement. It is suitable for aqueous expression and purification workflows but should not be treated as an independently active ribonuclease reagent or prepared in ethanol.
-
Plerixafor (AMD3100): A Translational CXCR4 Strategy
2026-08-24
Plerixafor (AMD3100) is more than a CXCR4 inhibitor: it is a mechanistic probe for tumor migration, hematopoietic stem cell mobilization, and immune-cell trafficking. This thought-leadership guide places the compound alongside emerging CXCR4 antagonist A1 and provides a practical framework for translating pathway biology into reproducible research decisions.
-
RNA Pol II Loss Triggers Apoptosis Beyond Transcription
2026-08-23
Harper et al. show that RNA polymerase II inhibition can kill cells through an active apoptotic response rather than through passive loss of transcription, mRNA, and protein. Their work identifies degradation of hypophosphorylated RNA Pol IIA as the initiating signal and provides a framework for interpreting the cytotoxicity of diverse transcription-targeting therapies.